BACKGROUND Inhibition of BCR-ABL tyrosine kinase activity has evolved as a mainstay of therapy for patients with chronic myeloid leukemia. However, a fraction of leukemic cells persists under targeted therapy and can lead to disease progression on cessation of treatment. DESIGN AND METHODS We analyzed bone marrow progenitor cells with the side population phenotype, and characterized the role ...

Background: Chronic myeloid leukemia is a clonal myeloproliferative disease which is characterized by bcr/abl translocation. With the emergence of tyrosine kinase inhibitors such as imatinib mesylate, significant improvement has been made in treatment of this disease. However, drug resistance against this medicine is still an obstacle. SIRT1 is a gene with deacetylase activity which has been de...

The presence of la-antigens and their relationship to the inhibitory effect of prostaglandin E on the proliferation of human CFU-GM was studied in animals and patients with chronic myeloid leukemia. Consistent reduction of normal colony formation to approximately 50% of baseline levels was observed using a monoclonal anti-human la antibody in a complement-dependent cytotoxicity assay titrated o...

BACKGROUND Tyrosine kinase inhibitors, such as imatinib, are not considered curative for chronic myeloid leukemia--regardless of the significant reduction of disease burden during treatment--since they do not affect the leukemic stem cells. However, the stochastic nature of hematopoiesis and recent clinical observations suggest that this view must be revisited. DESIGN AND METHODS We studied t...

hematopoietic cell transplantation (hct) is an accepted treatment for acute myeloid leukemia (aml) in first remission, the treatment of choice for chronic myeloid leukemia (cml) and high risk groups of all who relapse with conventional chemotherapy. we assessed results of hct for pediatric leukemia in our center. a total of 92 children, 63 with diagnose of aml, 23 with all and 6 with cml receiv...

Background: Acute Myeloid Leukemia (AML) with translocation (3,3) is a form of AML that may present de novo or may arise from a previous myelodysplastic syndrome. It is often associated with normal or elevated peripheral blood platelet count and increased bone marrow megakaryocytes with associated multi lineage dysplasia. A subset of patients present with hepatosplenomegaly while a few cases h...

BACKGROUND Micro-RNAs (miRNAs) control gene expression by destabilizing targeted transcripts and inhibiting their translation. Aberrant expression of miRNAs has been described in many human cancers, including chronic myeloid leukemia. Current first-line therapy for newly diagnosed chronic myeloid leukemia is imatinib mesylate, which typically produces a rapid hematologic response. However the e...

Chronic myeloid leukemia is a ph-positive myeloproliferative disease, which usually manifested by hyperleukocytosis and massive splenomegaly. rare in childhood adolescence, it accounts for 2 to 3 % of all leukemias cases. priapism manifestation chronic an urgent urological condition that requires timely treatment prevent long-term complications, particular, erectile dysfunction.This review pres...